Innealta Capital’s Apellis Pharmaceuticals APLS Stock Holding History

Innealta Capital’s Portfolio APLS Stock Details APLS Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2024 Q3	–	Sell	-56	Closed	-$2.15K	–	246
2024 Q2	$2.15K	Buy	+56	New	+$2.54K	﹤0.01%	1065

Other funds holding APLS

Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return

EcoR1 Capital San Francisco, California $2.36B AUM 204.53% 1-Year Est. Return

ACA

Avoro Capital Advisors New York $10.2B AUM 149.19% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

DTC

Deep Track Capital Greenwich, Connecticut $6.12B AUM 144% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return

Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

Braidwell Stamford, Connecticut $3B AUM 46.72% 1-Year Est. Return

Innealta Capital's APLS Position: Q3 2024 in Review

Innealta Capital sold out of Apellis Pharmaceuticals (APLS) in Q3 2024, closing a stake of 56 shares — an estimated $2.15K sold.

Innealta Capital first reported a position in APLS in Q2 2024 and held it in 1 quarter. The position peaked at $2.15K in Q2 2024. 265 funds tracked by Wall St. Rank hold APLS as of Q3 2024.

Innealta Capital reported no remaining Apellis Pharmaceuticals position as of Q3 2024 after selling out during the quarter.
Innealta Capital sold 56 Apellis Pharmaceuticals shares in Q3 2024, an estimated $2.15K.
Innealta Capital first reported a position in Apellis Pharmaceuticals in Q2 2024 and held it in 1 quarter.
Innealta Capital's Apellis Pharmaceuticals position peaked at $2.15K in Q2 2024.
265 funds tracked by Wall St. Rank held Apellis Pharmaceuticals as of Q3 2024.

Based on Innealta Capital's 13F filing for Q3 2024, filed 29 Oct 2024.